Erki sch772984

Manufactured by Selleck Chemicals

ERKi SCH772984 is a potent and selective inhibitor of the extracellular signal-regulated kinase (ERK) pathway. It functions by blocking the activity of ERK, a key component in the mitogen-activated protein kinase (MAPK) signaling cascade. The core function of ERKi SCH772984 is to modulate cellular responses by regulating the ERK signaling pathway.

Automatically generated - may contain errors

Lab products found in correlation

Brafi vemurafenib, by Selleck Chemicals (1 mentions) Meki trametinib, by Selleck Chemicals (1 mentions) Rocki gsk269962a, by Axon Medchem (1 mentions)

Spelling variants of this product

SCH772984 (223 citations)

2 protocols using erki sch772984

Pharmacological Inhibitors for Anticancer Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

BRAFi vemurafenib and ERKi SCH772984 were from Selleck Chemicals (Houston, TX), mTORi everolimus was from Novartis (Basel, Switzerland) and Sigma Aldrich, MEKi MEK162 was from MedChemExpress (Monmouth Junction, NJ), PI3Ki LY294002 was from Cell Signaling Technology (Danvers, MA). All drugs were dissolved in DMSO. For animal studies, the drugs were further diluted in 0.5% metylcellulose (Sigma-Aldrich).

Seip K., Fleten K.G., Barkovskaya A., Nygaard V., Haugen M.H., Engesæter B.Ø., Mælandsmo G.M, & Prasmickaite L. (2016). Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors. Oncotarget, 7(15), 19997-20015.

+ Open protocol

+ Expand

Chemical Agents for Cell Morphology

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemicals used in this study (stocks resuspended in DMSO unless otherwise stated): BRAFi PLX4720 and PLX4032 (Selleck), BRAFi Dabrafenib (GSK2118436, ChemieTek), MEKi Trametinib (GSK1120212, Selleck), MEKi PD184352 (Selleck), MEKi AZD6244 (Selleck), ERKi SCH772984 (Selleck), ROCKi GSK269962A (Axon Medchem), ROCKi H1152 (resuspended in water; Calbiochem), AGC kinase inhibitor and ROCKi AT13148 (Selleck), myosin II inhibitor blebbistatin (in 95% DMSO; Calbiochem). Concentrations used unless otherwise stated in other STAR Methods sections: 5 μM ROCKi GSK269962A, 5 μM ROCKi H1152, 5 μM ROCKi AT13148, 25 μM myosin II inhibitor blebbistatin, 5 μM BRAFi PLX4720. “Analysis of cell morphology” section lists the inhibitors and concentrations used for those experiments.

Orgaz J.L., Crosas-Molist E., Sadok A., Perdrix-Rosell A., Maiques O., Rodriguez-Hernandez I., Monger J., Mele S., Georgouli M., Bridgeman V., Karagiannis P., Lee R., Pandya P., Boehme L., Wallberg F., Tape C., Karagiannis S.N., Malanchi I, & Sanz-Moreno V. (2020). Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell, 37(1), 85-103.e9.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!